Bove v. Akpharma Inc.

Summary

The New Jersey Superior Court, Appellate Division, affirmed summary judgment for AkPharma Inc. and its CEO, holding that the plaintiff failed to establish an intentional wrong sufficient to overcome the Workers’ Compensation Act’s exclusivity bar. The court also affirmed denial of the plaintiff’s motion to strike the workers’ compensation defense but reversed sanctions imposed against the plaintiff’s attorneys under Rule 1:4-8. The claims arose from the plaintiff’s use of the NasoCell nasal spray and included battery, fraud, and product-liability theories.

Holdings

1. An employee may overcome the WCA exclusivity bar only by proving both that the employer knowingly exposed the employee to a substantial certainty of injury or death and that the resulting injury was not a fact of industrial life and was plainly beyond what the Legislature intended the WCA to immunize. Bove's evidence did not satisfy the conduct prong, so his civil claims were barred.
2. The sanctions order could not stand because the trial court failed to account for the temporal limitation on recoverable fees, defendants' safe-harbor letter did not specifically identify the WCA exclusivity bar, and the court made no finding that Bove's attorneys acted in bad faith or lacked an objectively reasonable belief in the claims.

Questions Presented

1. Whether Bove's civil claims against his employer and its CEO fell within the intentional-wrong exception to the Workers' Compensation Act's exclusivity provision.
2. Whether the trial court properly granted defendants summary judgment and denied Bove's motion to strike the WCA exclusivity defense.
3. Whether sanctions against Bove's attorneys under Rule 1:4-8 were proper despite the timing and content of defendants' safe-harbor notice and the absence of a finding of bad faith.

Disposition

other